ARTICLE | Clinical News

Plavix clopidogrel regulatory update

November 23, 2009 8:00 AM UTC

FDA notified healthcare professionals of new safety information concerning an interaction between Plavix clopidogrel and proton pump inhibitor (PPI) Prilosec omeprazole from AstraZeneca plc (LSE:AZN; NYSE:AZN, London, U.K.). FDA said data show that the effectiveness of Plavix is reduced when taken with omeprazole. The agency noted that other drugs that are expected to have a similar effect and should be avoided in combination with clopidogrel include: Vfend voriconazole from Pfizer Inc. (NYSE:PFE, New York, N.Y.), Intelence etravirine from Johnson & Johnson (NYSE:JNJ, New Brunswick, N.J.), Felbatol felbamate from Meda AB (SSE:MEDA, Solna, Sweden), Luvox CR fluvoxamine from Jazz Pharmaceuticals Inc. (NASDAQ:JAZZ, Palo Alto, Calif.), and generics ticlopidine, cimetidine, fluoxetine, fluconazole and ketoconazole. ...